"hepatocellular carcinoma patients" trang 3 - tải miễn phí từ tailieunhanh
Using nomogram of the Barcelona Clinic Liver Cancer system for treatment selection in patients with stage C hepatocellular carcinoma

Using nomogram of the Barcelona Clinic Liver Cancer system for treatment selection in patients with stage C hepatocellular carcinoma
9    66    1
Low expression of c-Myc protein predicts poor outcomes in patients with hepatocellular carcinoma after resection

Low expression of c-Myc protein predicts poor outcomes in patients with hepatocellular carcinoma after resection
14    70    1
Validation of the SNACOR clinical scoring system after transarterial chemoembolisation in patients with hepatocellular carcinoma

Validation of the SNACOR clinical scoring system after transarterial chemoembolisation in patients with hepatocellular carcinoma
8    34    1
Predictive value of gamma-glutamyl transpeptidase to lymphocyte count ratio in hepatocellular carcinoma patients with microvascular invasion

Predictive value of gamma-glutamyl transpeptidase to lymphocyte count ratio in hepatocellular carcinoma patients with microvascular invasion
9    46    1
A novel score based on serum apolipoprotein A-1 and C-reactive protein is a prognostic biomarker in hepatocellular carcinoma patients

A novel score based on serum apolipoprotein A-1 and C-reactive protein is a prognostic biomarker in hepatocellular carcinoma patients
13    50    1
CDCA5 overexpression is an Indicator of poor prognosis in patients with hepatocellular carcinoma (HCC)

CDCA5 overexpression is an Indicator of poor prognosis in patients with hepatocellular carcinoma (HCC)
10    71    1
Comparing stereotactic ablative radiotherapy (SABR) versus re-trans-catheter arterial chemoembolization (re-TACE) for hepatocellular carcinoma patients who had incomplete response after initial TACE (TASABR): A randomized controlled trial

Comparing stereotactic ablative radiotherapy (SABR) versus re-trans-catheter arterial chemoembolization (re-TACE) for hepatocellular carcinoma patients who had incomplete response after initial TACE (TASABR): A randomized controlled trial
11    33    5
Genome-wide copy number alteration and VEGFA amplification of circulating cell-free DNA as a biomarker in advanced hepatocellular carcinoma patients treated with Sorafenib

Genome-wide copy number alteration and VEGFA amplification of circulating cell-free DNA as a biomarker in advanced hepatocellular carcinoma patients treated with Sorafenib
13    31    1
Feasibility of dynamic risk assessment for patients with repeated trans-arterial chemoembolization for hepatocellular carcinoma

Feasibility of dynamic risk assessment for patients with repeated trans-arterial chemoembolization for hepatocellular carcinoma
10    31    1
Late presentation of hepatitis B among patients with newly diagnosed hepatocellular carcinoma: A national cohort study

Late presentation of hepatitis B among patients with newly diagnosed hepatocellular carcinoma: A national cohort study
8    37    1
Does fibrosis have an impact on survival of patients with hepatocellular carcinoma: Evidence from the SEER database?

Does fibrosis have an impact on survival of patients with hepatocellular carcinoma: Evidence from the SEER database?
9    79    1
The predictive powers of plasma trefoil factor 3 or its related micro RNAs for patients with hepatocellular carcinoma

The predictive powers of plasma trefoil factor 3 or its related micro RNAs for patients with hepatocellular carcinoma
6    38    1
Microvascular invasion has limited clinical values in hepatocellular carcinoma patients at Barcelona Clinic Liver Cancer (BCLC) stages 0 or B

Microvascular invasion has limited clinical values in hepatocellular carcinoma patients at Barcelona Clinic Liver Cancer (BCLC) stages 0 or B
8    43    1
Nomogram prediction of individual prognosis of patients with hepatocellular carcinoma

Nomogram prediction of individual prognosis of patients with hepatocellular carcinoma
11    57    1
High-mobility group protein box1 expression correlates with peritumoral macrophage infiltration and unfavorable prognosis in patients with hepatocellular carcinoma and cirrhosis

High-mobility group protein box1 expression correlates with peritumoral macrophage infiltration and unfavorable prognosis in patients with hepatocellular carcinoma and cirrhosis
10    49    1
Longitudinal alterations in health-related quality of life and its impact on the clinical course of patients with advanced hepatocellular carcinoma receiving sorafenib treatment

Longitudinal alterations in health-related quality of life and its impact on the clinical course of patients with advanced hepatocellular carcinoma receiving sorafenib treatment
9    46    1
Prognostic values of EORTC QLQ-C30 and QLQ-HCC18 index-scores in patients with hepatocellular carcinoma – clinical application of health-related quality-of-life data

Prognostic values of EORTC QLQ-C30 and QLQ-HCC18 index-scores in patients with hepatocellular carcinoma – clinical application of health-related quality-of-life data
11    58    1
Potential efficacy of therapies targeting intrahepatic lesions after sorafenib treatment of patients with hepatocellular carcinoma

Potential efficacy of therapies targeting intrahepatic lesions after sorafenib treatment of patients with hepatocellular carcinoma
9    29    1
Optimal staging system for predicting the prognosis of patients with hepatocellular carcinoma in China: A retrospective study

Optimal staging system for predicting the prognosis of patients with hepatocellular carcinoma in China: A retrospective study
9    52    1
Evaluation of KIF23 variant 1 expression and relevance as a novel prognostic factor in patients with hepatocellular carcinoma

Evaluation of KIF23 variant 1 expression and relevance as a novel prognostic factor in patients with hepatocellular carcinoma
9    45    1